|Perry Kim, PhD
Assistant Scientific Director
Perry Kim, PhD, joined the Canadian Frailty Network in July of 2014. He has over 20 years’ research and technology commercialization experience in both the private sector and academia, including working as Chief Operating Officer at AtheroChem Inc., a biopharmaceutical focused developing novel cardiovascular treatments. Perry also has experience in the university commercialization and KTEE areas, as the Director of Commercial Development at PARTEQ Innovations, the technology commercialization arm of Queen’s University, and in the University of Ottawa’s Technology Transfer and Business Enterprise Office. He holds an adjunct assistant professor position with the Department of Biomedical and Molecular Sciences and was formerly an assistant professor in the Department of Pharmacology and Toxicology and at the School of Environmental studies, all at Queen’s. Perry has a PhD in Toxicology and Pharmacology from University of Toronto and completed a postdoctoral fellowship at the Department of Molecular Genetics and Microbiology, University of New Mexico.